Probably the most thoroughly investigated drug targeting vimentin IFs is the tumor inhibitor Withaferin A (WFA), derived from the plant Withania somnifera [120], which was found to target and directly bind vimentin in an effort to find the mode of action related to its antiangiogenic properties [123]. The gene discussed is VIM; the disease is neoplasm.